Skip to main
TWST

TWST Stock Forecast & Price Target

TWST Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Twist Bioscience is at the forefront of the rapidly expanding synthetic biology industry, with their innovative and efficient DNA synthesis platform positioning them for long-term growth. The recent momentum driven by AI drug discovery is a strong indication of the company's potential for continued expansion and success in their core NGS segment. Despite a strong YTD performance, the stock still remains attractive, with upside potential from multiple avenues such as expanding manufacturing capacity, possible acquisitions, and surprise product launches. The potential for continued growth, profitability, and operating leverage make Twist Bioscience a compelling investment opportunity in the life science tools sector, with a BUY rating and a price target of $60 based on a SOTP valuation method.

Bears say

Twist Bioscience is currently experiencing strong revenue growth and beat earnings expectations in F2Q26, positioning them for continued success in the near future. However, there are risks related to their margins and operating leverage, and any slowdown in end-market growth for NGS products or unexpected competition could impact their growth potential. Additionally, while Twist has seen growth in all geographic regions, they are heavily dependent on the Americas for revenue, which could pose a risk in terms of diversification.

TWST has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Twist Bioscience Corp (TWST) Forecast

Analysts have given TWST a Buy based on their latest research and market trends.

According to 9 analysts, TWST has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Twist Bioscience Corp (TWST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.